Angela Walling
Family · Carthage, NCNPI 1679508253
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $100,645 of the $108,423 with a category attached, or 92.8%. Organon accounts for 90.6% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2024 at $35,576 and has fallen 58.1% since, to $14,919 in 2025. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 393 payments — averaging $275.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$98K
- Merck$6K
- Lilly USA, LLC$717
- Novo Nordisk$708
- AstraZeneca$606
- AbbVie$464
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$100,64593%
- Travel & lodging$2,8243%
- Food & beverage$4,8424%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 197 | $98,226 |
| Merck | 8 | $6,211 |
| Lilly USA, LLC | 39 | $717 |
| Novo Nordisk | 41 | $708 |
| AstraZeneca | 19 | $606 |
| AbbVie | 24 | $464 |
| Bayer | 4 | $272 |
| Idorsia Pharmaceuticals US Inc | 9 | $244 |
| Boehringer Ingelheim | 10 | $182 |
| Astellas Pharma US Inc | 4 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $99 |
| GSK | 4 | $77 |
| Pfizer | 4 | $69 |
| Therapeuticsmd, Inc. | 4 | $69 |
| Exact Sciences | 4 | $68 |
| Abbott | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Avion Pharmaceuticals | 2 | $25 |
| Coopersurgical, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $17 |
| Millicent US Inc | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,423 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 58 | $43,103 |
| MounjaroTirzepatide | 36 | $38,234 |
| FarxigaDapagliflozin Propanediol | 37 | $33,899 |
| XareltoRivaroxaban | 18 | $25,009 |
| TrulicityDulaglutide | 22 | $24,904 |
| OzempicSemaglutide | 18 | $23,586 |
| JardianceEmpagliflozin | 24 | $22,473 |
| LinzessLinaclotide | 11 | $10,086 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,622 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,899 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,605 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $2,505 |
| Bupropion XlBupropion Hcl | 56 | $1,544 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,468 |
| Levothyroxine Sodium | 99 | $1,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $717 | $63,13858 claims |
| PfizerEliquis | $69 | $43,10358 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $606 | $42,52151 claims |
| Novo NordiskOzempic | $708 | $23,58618 claims |
| Boehringer IngelheimJardiance | $182 | $22,47324 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $77 | $13,50327 claims |
| AbbVieLinzess, Synthroid | $464 | $10,50822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Carthage
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.